Pharmacy and Poisons Board

Pharmacy and Poisons Board

Ensuring Safety, Quality and Efficacy of Medicines

Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 46, showing 5 Applications out of 228 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/19/06/01   EPI 003
    A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa.   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
1. Ahero clinical triasl unit (Kisumu county)
2. KEMI CDC (Siaya county)
 
Trial Status not yet recruiting
Protocol Date 11-10-2017
View

2.

ECCT/19/05/02   ETNA
    EVALUATION OF TECHNOLOGIES FOR NEONATES IN AFRICA   
Principal Investigator(s)
1. PROF WILLIAM MAINA MACHARIA
Site(s) in Kenya
1. AGA KHAN UNIVERSITY HOSPITAL (Nairobi City county)
2. PUMWANI MATERNITY HOSPITAL (Nairobi City county)
 
Trial Status recruiting
Protocol Date 25-02-2019
View

3.

ECCT/19/04/04   Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya
    Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya:two cluster-randomized controlled trials in pregnant women and their offspring and in 6-59 months old children comparing an agricultural intervention alone with a combined agricultural, nutrition and WASH intervention.       
Principal Investigator(s)
1. Rita Wegmuller
Site(s) in Kenya
1. Kakamega and Bungoma (Kakamega county)
 
Trial Status (not set!)
Protocol Date 11-04-2019
View

4.

ECCT/19/04/02   NADIA \"Nucleosides And Darunavir/Dolutegravir In Africa\"
    A randomised controlled trial of darunavir versus dolutegravir and tenofovir versus zidovudine in second-line antiretroviral therapy regimens for the public health approach in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
Trial Status (not set!)
Protocol Date 14-11-2018
View

5.

ECCT/19/04/03   Phase III pediatric study with the L-PZQ ODTs
    An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®)   
Principal Investigator(s)
1. Maurice Reuben Odiere
Site(s) in Kenya
KEMRI-Centre for Global Health Research (CGHR)
 
Trial Status not yet recruiting
Protocol Date 20-02-2019
View